Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,752,642
  • Shares Outstanding, K 193,863
  • Annual Sales, $ 502,080 K
  • Annual Income, $ -724,930 K
  • EBIT $ -523 M
  • EBITDA $ -512 M
  • 60-Month Beta 1.13
  • Price/Sales 27.43
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 59.24% (-1.40%)
  • Historical Volatility 74.16%
  • IV Percentile 66%
  • IV Rank 49.93%
  • IV High 80.30% on 02/05/26
  • IV Low 38.24% on 06/12/25
  • Expected Move (DTE 1) 2.86 (4.09%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 742
  • Volume Avg (30-Day) 1,644
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 53,519
  • Open Int (30-Day) 49,923
  • Expected Range 67.26 to 72.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.71
  • Number of Estimates 10
  • High Estimate -0.50
  • Low Estimate -0.91
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +19.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.77 +11.71%
on 03/03/26
75.90 -7.62%
on 03/10/26
-3.81 (-5.15%)
since 02/18/26
3-Month
62.77 +11.71%
on 03/03/26
84.94 -17.45%
on 02/12/26
-4.02 (-5.42%)
since 12/18/25
52-Week
28.33 +147.51%
on 04/09/25
84.94 -17.45%
on 02/12/26
+37.93 (+117.83%)
since 03/18/25

Most Recent Stories

More News
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified...

BBIO : 70.12 (-1.16%)
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 70.12 (-1.16%)
BridgeBio Pharma: Q4 Earnings Snapshot

BridgeBio Pharma: Q4 Earnings Snapshot

BBIO : 70.12 (-1.16%)
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively BridgeBio...

BBIO : 70.12 (-1.16%)
BridgeBio to Participate in March Investor Conferences

PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 70.12 (-1.16%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 70.12 (-1.16%)
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 70.12 (-1.16%)
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p

BBIO : 70.12 (-1.16%)
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first...

BBIO : 70.12 (-1.16%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...

BBIO : 70.12 (-1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 72.54
2nd Resistance Point 71.94
1st Resistance Point 71.03
Last Price 70.12
1st Support Level 69.51
2nd Support Level 68.91
3rd Support Level 68.00

See More

52-Week High 84.94
Last Price 70.12
Fibonacci 61.8% 63.31
Fibonacci 50% 56.64
Fibonacci 38.2% 49.96
52-Week Low 28.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar